In 2026, data integrity and privacy risks don’t sit in one department—they show up anywhere regulated data is created, reviewed, transferred, or relied on across the life sciences ecosystem (quality, IT, validation, labs, clinical operations, manufacturing, and vendor/supplier teams). The underlying expectation behind 21 CFR Part 11 is that electronic records and e-signatures remain trustworthy and controlled when they’re created, modified, maintained, retrieved, or transmitted under FDA record requirements.
What’s raising the stakes is the modern operating model: SaaS platforms, cloud hosting, remote access, integrations/APIs, and vendor support logins. That’s where common breakdowns happen—unclear roles/permissions, excessive admin rights, weak password controls, incomplete audit-trail review, uncontrolled exports, and SOP gaps where day-to-day practice drifts from written procedure.
FDA warning letters and related compliance records repeatedly point to these same themes in real operations—such as analysts retaining administrative privileges, audit trails not enabled or not effectively used, and gaps in backup/completeness controls for laboratory data. They also highlight investigation failures like invalidating original failed results without a scientifically sound root cause and leaning on “passing” retests—exactly the kind of pattern that becomes difficult to defend when electronic records, audit trails, and access controls don’t support transparent review.
The goal isn’t more complexity—it’s clearer governance, clearer controls, and evidence you can stand behind during inspections. FDA guidance is explicit that audit trails are part of the record and should be reviewed in a way that aligns with the required record-review frequency, and EU GMP Annex 11 reinforces expectations around validation/risk management for computerized systems used in GMP activities. On the privacy side, GDPR adds real exposure around accountability and third-party processing (including potentially significant administrative fines for serious infringements).
This timely webinar, led by industry expert David Nettleton, aims to provide life sciences professionals with practical knowledge, strategies, and tools to navigate the complex landscape of data integrity and privacy compliance—focused specifically on 21 CFR Part 11, SaaS/Cloud considerations, and EU GDPR requirements.
You should attend because in 2026 the “failure modes” for data integrity and privacy are rarely dramatic—they’re usually everyday workflow gaps (permissions, admin access, audit-trail review, reanalysis handling, uncontrolled exports, vendor access) that quietly accumulate until an inspection or audit forces a painful, time-consuming cleanup. This session helps you recognize those weak points early and frame them in the language regulators expect.
You’ll also benefit if your environment is hybrid (local systems + SaaS/cloud + spreadsheets + vendor portals). The webinar is designed to connect what Part 11 / Annex 11 require with how teams actually operate, so Quality, IT, Validation, and operational groups can align on practical controls and SOP expectations—without turning your program into an overbuilt, never-ending validation project.
Finally, you’ll leave with a clearer, more defensible approach to electronic records/e-signatures and data privacy basics that supports day-to-day decision making and vendor conversations—so you can reduce inspection risk, avoid avoidable findings, and respond faster when questions come up.
This webinar is designed for life sciences teams responsible for governing, validating, operating, or auditing computerized systems and regulated data—especially where electronic records/e-signatures, SaaS/cloud hosting, and privacy obligations intersect. Those include:
Carolyn Troiano has more than 35 years of experience in computer system validation in the tobacco, pharmaceutical, medical device and other FDA-regulated industries. She has worked directly, or on a consulting basis, for many of the larger pharmaceutical and tobacco companies in the US and Europe. She is currently building an FDA computer system validation compliance strategy at a vapor company. Carolyn has participated in industry conferences, and is currently active in the Association of Information Technology Professionals (AITP), and Project Management Institute (PMI) chapters in the Richmond, VA area. Carolyn also volunteers for the PMI’s Educational Fund as a project management instructor for non-profit organizations.